Floatz logo

Tyra-300

Non-muscle-invasive Bladder Cancer

Tyra Biosciences, IncPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Non-muscle-invasive Bladder Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3B
Bacillus Calmette-Guerin
Merck Sharp & Dohme LLC
Phase 3B
Polio/Rhinovirus Recombinant
Istari Oncology, Inc.
Phase 1/2CC

Same molecule, other indications

Tyra-300 is also rated in:

urothelial carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR3 Gene MutationDormant
CCC
Indicative ·
48 / 100
View asset →
FGFR3 Gene AlterationDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →